Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by crow27on Feb 11, 2021 1:26pm
112 Views
Post# 32542222

RE:RE:RE:IR responce

RE:RE:RE:IR responceRight off the bat Nuance gave ATB 20 million because they want this license. Nuance now has to do all the heavy lifting to run trials/get approval/distribute the product and sell the product.
ATB will get the other 80 million in stages once Nuance moves this through the system or through certain stages. ATB is actually doing nothing for this 80 million. They get this money when Nuance reaches their own milestones.
And then to even sweeten the deal more Nuance gave ATB adouble digit royalty on sales.
If Nuance fails to be able to bring this to market then ATB will only get a little bit of that 80 million.
Thats the way I see it but I could be wrong but I do not think I am. Thats why this is such a big win for ATB. Of course ATB will be involved with certain things but it really is a super payday for ATB if this does pass the trials and sales take-off.
<< Previous
Bullboard Posts
Next >>